Prognosis
Biogen to Start Screening Patients for Alzheimer’s Drug Trial
This article is for subscribers only.
Biogen Inc. will begin screening patients in May for a four-year study aimed at confirming the effectiveness of Aduhelm, the company’s controversial Alzheimer’s medicine.
The drugmaker submitted a final protocol for the global trial to the U.S. Food and Drug Administration and intends to enroll about 1,500 patients, according to a statement Wednesday.